H Desilva

Heshani Desilva 2 collaborations

Toni K Choueiri 1 collaboration

Harriet Kluger 1 collaboration

Saby George 1 collaboration

Scott S Tykodi 1 collaboration

Timothy M Kuzel 1 collaboration

Ruth Perets 1 collaboration

Suresh Nair 1 collaboration

Giuseppe Procopio 1 collaboration

Michael A Carducci 1 collaboration

Vincent Castonguay 1 collaboration

Edmund Folefac 1 collaboration

Chung-Han Lee 1 collaboration

Sebastien J Hotte 1 collaboration

Wilson H Miller 1 collaboration

Shruti Shally Saggi 1 collaboration

Chung-Wei Lee 1 collaboration

Prabhu Bhagavatheeswaran 1 collaboration

Robert J Motzer 1 collaboration

Bernard Escudier 1 collaboration

N M Tannir 1 collaboration

L Albigès 1 collaboration

D F McDermott 1 collaboration

M Burotto 1 collaboration

T K Choueiri 1 collaboration

H J Hammers 1 collaboration

P Barthélémy 1 collaboration

E R Plimack 1 collaboration

C Porta 1 collaboration

S George 1 collaboration

F Donskov 1 collaboration

M B Atkins 1 collaboration

H Gurney 1 collaboration

C K Kollmannsberger 1 collaboration

M-O Grimm 1 collaboration

C Barrios 1 collaboration

Y Tomita 1 collaboration

D Castellano 1 collaboration

V Grünwald 1 collaboration

B I Rini 1 collaboration

R Jiang 1 collaboration

V Federov 1 collaboration

C-W Lee 1 collaboration

R J Motzer 1 collaboration

Junchen Gu 1 collaboration

Cindy Wang 1 collaboration

Carolyn Cao 1 collaboration

Jinwen Huang 1 collaboration

Sandra Holzhauer 1 collaboration

Erin M Wesley 1 collaboration

Douglas B Evans 1 collaboration

Joseph Benci 1 collaboration

Michael Wichroski 1 collaboration

Susan Wee 1 collaboration

Matthew J Riese 1 collaboration

Affiliations

Publications (3)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.

DGKζ exerts greater control than DGKα over CD8

Réseau de co-auteurs